Apixaban + ASA + Clopidogrel 75mg

Phase 3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Critical Limb Ischemia

Conditions

Critical Limb Ischemia

Trial Timeline

Jan 9, 2020 → May 2, 2022

NCT ID

NCT04229264

About Apixaban + ASA + Clopidogrel 75mg

Apixaban + ASA + Clopidogrel 75mg is a phase 3 stage product being developed by Pfizer for Critical Limb Ischemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT04229264. Target conditions include Critical Limb Ischemia.

What happened to similar drugs?

4 of 8 similar drugs in Critical Limb Ischemia were approved

Approved (4) Terminated (2) Active (2)

✅DaptomycinMerckApproved

✅Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.AmgenApproved

✅Colchicine (Colcrys®) + placebo + allopurinolRegeneron PharmaceuticalsApproved

✅Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35EBaxterApproved

🔄Rilonacept 80 mg + Rilonacept 160 mgRegeneron PharmaceuticalsPhase 3

❌Remodulin® (treprostinil sodium) InjectionUnited TherapeuticsPhase 3

❌Olimel (5.7%E / N9E)BaxterPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04229264	Phase 3	UNKNOWN	Jan 9, 2020	May 2, 2022	Critical Limb Ischemia

Competing Products

13 competing products in Critical Limb Ischemia

See all competitors

Product	Company	Stage	Hype Score
Daptomycin	Merck	Approved	43
Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose	Merck	Phase 1	29
Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.	Amgen	Approved	39
intensive insulin therapy to maintain normoglycemia	Novo Nordisk	Phase 2	35
Midazolam + Dexmedetomidine	Pfizer	Pre-clinical	26
Colchicine (Colcrys®) + placebo + allopurinol	Regeneron Pharmaceuticals	Approved	43
Rilonacept 80 mg + Rilonacept 160 mg	Regeneron Pharmaceuticals	Phase 3	40
treprostinil dienthanolmine sustained release + Placebo	United Therapeutics	Phase 2	32
Remodulin® (treprostinil sodium) Injection	United Therapeutics	Phase 3	29
Olimel (5.7%E / N9E)	Baxter	Phase 3	29
Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E	Baxter	Approved	44
RJX + Placebo	ICON plc.	Phase 1	26
Ixmyelocel-T	Vericel	Phase 3	34